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b-Defensins comprise a family of cationic, antimicrobial and chemoattractant peptides. The six
cysteine canonical motif is retained throughout evolution and the disulphide connectivities
stabilise the conserved monomer structure. A murine b-defensin gene (Defr1)p r e s e n ti nt h e
main defensin cluster of C57B1/6 mice, encodes a peptide with only ﬁve of the canonical six
cysteine residues. In other inbred strains of mice, the allele encodes Defb8, which has the six
cysteine motif. We show here that in common with six cysteine b-defensins, defensin-related
peptide 1 (Defr1) displays chemoattractant activity for CD4
1 T cells and immature DC (iDC), but
not mature DC cells or neutrophils. Murine Defb2 replicates this pattern of attraction. Defb8 is
also able to attract iDC but not mature DC. Synthetic analogues of Defr1 with the six cysteines
restored (Defr1 Y5C) or with only a single cysteine (Defr1-1c
V)c h e m o a t t r a c tC D 4
1 T cells with
reduced activity, but do not chemoattract DC. b-Defensins have previously been shown to
attract iDC through CC receptor 6 (CCR6) but neither Defr1 or its related peptides nor Defb8,
chemoattract cells overexpressing CCR6. Thus, we demonstrate that the canonical six cysteines
of b-defensins are not required for the chemoattractant activity of Defr1 and that neither Defr1
nor the six cysteine polymorphic variant allele Defb8, act through CCR6.
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Introduction
b-Defensins are small, cationic host defence peptides and
are considered important components of the immune
system with potent antimicrobial activity, chemoattractant and
immune-enhancing activity [1, 2]. Members of this family
contain six cysteine residues highly conserved throughout
evolution and have an identiﬁable consensus sequence of
x2–10Cx5–7(G/A)xCx3–4Cx9–13Cx4–7CCxn where x is any amino
acid [2].
Human b-defensins (HBD) have been shown to act as
chemoattractants for immature DC (iDC) and memory T cells [3].
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via CC receptor 6 (CCR6), which is preferentially expressed by iDC
and CD4
1 T cells [3] and thus they promote adaptive immune
responses by recruiting DC and T cells to sites of microbial inva-
sion. HBD3 is another b-defensin family member and is expressed
predominantly in the lung, reproductive tract and skin and is
induced by microbial stimuli and proinﬂammatory cytokines
[4, 5]. It is also a chemoattractant through CCR6 but, in addition,
induces migration of monocytes which have been shown not to
express this receptor[6]. Recently, HBD1 and 3 have been shown
to be able to bind to melanocortin receptor 1 and overexpression
of the dog orthologue of HBD3 in mice alters coat colour [7].
Despite considerable sequence variation between b-defensin
peptides, the topology of the b-defensin structure has been reported
to be similar and stabilised by the three intramolecular disulphide
bonds [8]. The connectivity of these bonds inﬂuences the afﬁnity of
synthetic HBD3 peptide’s interaction with the CCR6 receptor [6] but
we have recently shown that a peptide with only the ﬁfth cysteine of
the six cysteine motif in this peptide is sufﬁcient to induce the
migration of both CCR6 expressing cells and monocytes [9].
The mouse genome also encodes b-defensin genes in four
syntenic gene clusters [10] with some genes having clear human
orthologues whereas others are rodent speciﬁc [11]. Mouse gene
Defb1 is the orthologue of human DEFB1 (encoding peptide
HBD1), Defb4 is the orthologue of DEFB4 (encoding peptide
HBD2) and Defb14 is the clear orthologue of DEFB103 (encoding
HBD3) [11]. Defb14 peptide has been shown to chemoattract
cells expressing human or mouse CCR6 [9, 12] and monocytes, so
is functionally similar to its orthologous peptide HBD3.
The murine b-defensin Defb2, encoding peptide mBD2 is in a
rodent-speciﬁc clade with physically adjacent genes Defb9, 10
and 11. Defb2 has been studied as a fusion peptide with a non-
immunogenic tumour antigen and binds murine CCR6, similarly
to inﬂammatory chemokine macrophage-inﬂammatory protein
3alpha (CCL20), and to chemoattract bone marrow-derived iDC,
but not mature DC (mDC) [13].
Murine b-defensin-related peptide (Defr1), is also encoded by
a gene present in the main b-defensin locus on chromosome 8
and is part of a rodent-speciﬁc clade [11]. It encodes a peptide
sequence that contains only ﬁve cysteine residues instead of the
canonical six, although it still retains potent antimicrobial activity
[14]. This activity is dependant upon its ability to form a covalent
dimer as the activity is less when the peptide is reduced [15]. An
artiﬁcial peptide analogue (Defr1-Y5C) has the tyrosine present
at residue 5 in Defr1 replaced by a cysteine and this restores the
canonical six cysteine motif [15]. This peptide displays poor
antimicrobial activity believed to be due to the peptide’s inability
to form covalent dimer species [16]. Defr1-Y5C, oxidises to
stabilise its structure through the three canonical defensin
disulphide bonds Cys
I–Cys
V, Cys
II–Cys
IV, Cys
III–Cys
VI [8] and
forms a non-covalent dimmer [15]. Defr1 is present in the
C57B1/6 inbred mouse genome but in other strains of mice
sequenced, this gene has three nucleotide changes resulting in
three amino acid substitutions. This polymorphic allele is Defb8
(Table 1), which has been shown to be a chemoattractant for
macrophages and mast cells [17].
In this study, we show that Defr1, like other b-defensins
described to date, displays chemoattractant properties for iDC
and CD4
1 T cells. Analogues with or without the canonical six
cysteine motif partially replicate this activity, being attractants
only for CD4 T cells and not iDC. Defb8 does show chemoat-
tractant ability for iDC. However, unlike other b-defensins,
neither Defr1 nor the six cysteine allele Defb8 mediate
chemoattractant activity through CCR6.
Results
Defr1 can chemoattract iDC but not mDC
Defr1 (see Table 1 for sequences of peptides) was tested to see
whether it could chemoattract iDC as had been described for the
six cysteine peptides HBD2 and a Defb2 (mBD2) fusion [3, 18].
Cells were isolated from the bone marrow of mice and cultured in
the presence of GM-CSF for 6 days to generate an iDC-enriched
population (d6iDC). Statistically signiﬁcant (po0.05) migration
of d6iDC is observed in response to both Defr1 and the mature
Defb2 peptide (Fig. 1A). The peak activity for Defb2 is between
10 and 100ng/mL and gives a migratory index (MI) of 2.75 at
10ng/mL. The peak migration in response to Defr1 is between 10
and 100ng/mL and gives a peak MI of 2.35.
FACS analysis of the cell population for various DC surface
markers is shown in Supporting Information Table S1. The
analyses reveal that 51.5% of these d6iDC cells were double
positive for CD11c and MHC II, 73.5% expressed CD54 (ICAM-1)
and 95.88% expressed CD86. Contamination from granulocytes
Table 1. Defr1 and analogue peptide sequences used in this study
a)
Peptide Sequence 1
Defr1 1 6
Defr1-Y5C 1 6
Defr1-1c
V 1 6
Defb8 1 6
Defb2 15
a) Comparison of synthetic peptide sequences. Amino acids at the cysteine position are in bold.1indicates net charge of monomer. Changes
between Defr1 and Defb8 are highlighted in grey.
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expression, was 5%. As these cell types are the main contaminant,
these results suggest that approximately 70% of the 6-day
population is DC.
The migratory responses of iDC that had been cultured in the
presence of GM-CSF for 7 days (d7iDC) were also assessed to
investigate if culture-period or developmental stage of the
DC affected the migration in response to Defb2 or Defr1
(Fig. 1B).The peak level of migration of d7iDC in response to
Defb2 is again between 10 and 100ng/mL, the MI is 3.0. The
concentration of Defr1 that induces the highest level of migration
is 1ng/mL, lower than the 10ng/mL that gave the peak
concentration of migration for d6iDC. The level of migration is
also slightly higher than that observed for Defb2, with an MI of
almost 3.5. Defr1 at a concentration of 0.1ng/mL also induces
signiﬁcant migration (po 0.05) with an MI of 2.5. All concentra-
tions of Defb2 tested induce statistically signiﬁcant migration
compared with the control (po0.05).
FACS analysis of the d7iDC cell population (shown in
Supporting Information Table S1) reveals that the percentage of
cells positive for MHC II and CD11c was 62.50; and is higher in
these older cells than was seen with d6iDC (51.48%). Moreover,
the percentage of cells that are positive for either CD11c
(94.14%) or MHC II (84%) is also higher indicating increased
levels of expression. The percentages of cells positive for CD86
(96.19%) or CD54 (77.33%) are approximately the same as for
d6iDC, but the mean ﬂuorescence is in each case higher, again
suggesting that the level of expression of the surface antigens is
higher. The percentage of Gr11Granulocyte (26.96) and B-cell
contamination (5.14%) are similar to those seen in the d6iDC
populations.
The experiments were then repeated with cells that 24h
prior to the experiment were exposed to LPS to induce maturity.
mDC do not show signiﬁcant migration in response to either
Defb2 or Defr1 (Fig. 1C). However, in response to the
positive control (CCL19), statistically signiﬁcant migration was
observed.
FACS of the mDC reveals a population that has a higher mean
ﬂuorescence in the populations of cells expressing CD11c or
MHC II (319.34 and 422.37 respectively). A greater percentage of
cells that was double positive for MHC II and CD11c is seen
(71.25%). CD86 and CD54 mean ﬂuorescence levels were also
elevated compared with iDC (1124.2 and 874.74), whereas levels
of contamination by granulocytes (Gr11) or B cells (B220) were
similar to those observed in previous populations (24.74 and
4.98%).
Neutrophils were then isolated from the peritoneum of mice
and incubated with the peptides as described. The isolated cells
were conﬁrmed as neutrophils by morphology and all popula-
tions used were at least 90% pure. The neutrophils showed
signiﬁcant migration in response to 45ng/mL of the positive
control, N-formylmethionyl leucyl phenyalanine but neither
Defb2 nor Defr1 induced signiﬁcant cell migration (Fig. 1D).
Neutrophils have only been reported to display chemoattractant
properties with HBD2 after activation with TNF-a [19] but
Figure 1. Response of DC to b-defensins. The migratory response
of (A and B) iDC cultured in the presence of GM-CSF for (A) 6 days and
(B) 7 days, (C) LPS-mDC and (D) neutrophils to the indicated molecules
was assessed. CCL20 was included as a positive control; CM is control
medium without peptide. Data shown are the mean number of cells
migrated per high power ﬁeld of view from a total of nine random ﬁelds
from three replicate wells and are from one experiment of a minimum
of three. Error bars represent SD of all nine replicate counts. Figure 1E
shows the migratory response of iDC or mDC to Defr1 analogues Defr1
Y5C and Defr1-1c
V. iDC (6 days cultured in GM-CSF) and mDC. The
controls used were Defb8 (labelled 1), RANTES/CCL5 (labelled 2) and
SDF-1a/CXCL12 (labelled 3). p o 0.05, signiﬁcantly higher cell number
than medium alone control.
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LL-37 [20]
In order to determine whether altering the presence or
absence of the cysteine residues in Defr1 altered its ability to
chemoattract the iDC, we tested six cysteine artiﬁcial peptide
analogue Defr1 Y5C or the single cysteine analogue Defr1-1c
V
(see Table 1 for sequence) against iDC and mDC. Neither peptide
could induce migration of these cells (see Fig. 1E). Thus, both
sequence and structure are important for Defr1 to induce
migration of iDC.
b-defensins with or without the canonical
disulphide connectivity can chemoattract
CD4
1 T lymphocytes
In order to investigate whether Defr1 also was a chemoattractant
for CD4
1 T lymphocytes, CD4
1 cells were isolated from both
human and mouse and subjected to chemotaxis analysis (Fig. 2).
Defr1 displays chemotactic activity for CD4
1 T cells from both
these sources with an optimal concentration of 10ng/mL and an
MI of 8 for the human cells (Fig. 2A) and 2.5 for mouse cells
(Fig. 2B). Defr1 Y5C and the single cysteine analogue Defr1-1c
V
also revealed chemoattractant ability but this activity is reduced.
Against the human cells, these two peptides had an optimal
concentration at 100ng/mL and an MI at this value of 5.5
(Fig. 2). Against mouse cells, the only concentration that was
signiﬁcantly different from the control was 100ng/mL, compared
with 10ng/mL for Defr1 and the MI for Defr1 Y5C and Defr1-1C
V
was only 1.5 (Fig. 2B). The chemoattractant activities of the six
cysteine defensin (Defr1Y5C) and the single cysteine defensin
(Defr1-1C
V) are not signiﬁcantly different from each other and
both had reduced activity compared with the parent molecule.
Defr1 and Defb8 are allelic
Defr1 was originally isolated and sequenced from C57Bl/6 mouse
genomic DNA [14]. However, a related gene has been described
which has three nucleotide changes in the coding sequence of the
second exon and this would result in three amino acid changes in
the mature peptide sequence (see Table 1). This variant was
termed Defb8 (peptide mBD8) as it had six cysteines and the
synthetic peptide structure has been determined [8]. We devised
a PCR that distinguishes the two alleles (see the Materials and
methods) and allows us to visualise which allele is present in
different rodent strains and species (Fig. 3). The Defb8 allele is
present in the Mus musculus inbred strains 129, A/J, Balb/c, DBA
and M. musculus. Castaneus. The Defr1 allele is only present in
M. musculus inbred strain C57Bl/6 and M. domesticus Lewes
indicating that the Defr1 allele came from the M. Domesticus
contribution to the C57/Bl6 genome.
Figure 2. Defr1 and its analogues are chemoattractants for human and
mouse CD4
1 T cells. The ability of Defr1 and its analogues to
chemoattract (A) human and (B) CD4
1 T cells was assessed by
chemotaxis. CCL20 (Mip3a) and CXCL12a (Stromal cell-derived factor
1a, SDF1a) were used as positive controls in (A) and (B) respectively. CM
is control medium without peptide. Data shown are the mean number
of cells migrated per high power ﬁeld of view from a total of nine
random ﬁelds from three replicate wells and are from one experiment
of a minimum of three. Error bars represent SD of all nine replicate
counts. p o 0.05 (one-tailed Student’s t-test), signiﬁcantly higher cell
number than medium alone control.
Figure 3. Distribution of Defr1 and Defb8 in various mouse strains.
A PCR speciﬁc for either Defr1 (top panel) or Defb8 (second panel) was
used against DNA isolated from a series of inbred and outbred mouse
species. The ethidium stained gels (two upper panels) were blotted and
hybridised with an internal oligonucleotide probe that recognises both
Defr1 and Defb8 (two lower panels).
Eur. J. Immunol. 2009. 39: 1353–1360 Karen Taylor et al. 1356
& 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euDefr1 nor its allele Defb8 act through the CCR6
chemokine receptor
In order to determine whether Defb8 could chemoattract iDC like
Defr1, we tested both iDC and mDC with the Defb8 peptide.
Defb8 was made synthetically and its cysteine disulphide
connectivities were veriﬁed as being canonical (C
I–C
V;C
II–C
IV;
C
III–C
VI) by protease digestion and mass spectrometry analysis
(Table S2 in Supporting Information). Figure 4A demonstrates
that like its allele Defr1, Defb8 can chemoattract iDC, but
not mDC.
Defensins have been reported to chemoattract CD4 T cells
through CCR6, for which CCL20 is the recognised ligand and is
present on CD4 T cells and iDC but not mDC [3, 6]. We tested
whether our Defr1/Defb8 peptides can chemoattract cells that
overexpress human CCR6. Figure 4B shows that although CCL20,
the recognised chemokine ligand for the CCR6 receptor, can
chemoattract these cells, neither Defr1 nor the six cysteine allele
Defb8, can chemoattract these cells that express CCR6 (Fig. 4B).
The artiﬁcial analogues (Defr1-Y5C and Defr1-1c
V) are also
unable to chemoattract these cells.
Discussion
The b-defensins have been described as a link between adaptive and
innate immunity. HBD1, 2 and 3 have been shown to chemoattract
CD4
1 T cells and iDC [3, 6]. Biragyn et al. revealed that murine
b-defensin 2 when coupled to lymphoma antigen sFv, can induce
migration of iDC but not mDC and bind CCR6 [13]. DC exist in both
an immature and mature state, the former characterised by their
ability to endocytose and process antigens whereas the latter
displays elevated levels of antigen presentation [21]. The matura-
tion process is initiated by stimuli such as TNF-a or LPS. We show
here that mature Defb2, Defr1 and Defb8 peptides also chemo-
attract iDC but not mature cells produced after induction with LPS.
However the synthetic analogues Defr1-Y5C and Defr1-1c
V,a r en o t
able to induce chemoattraction of either iDC or mDC.
Further evaluation of the cells which are attracted to the Defr1
peptide shows that, in addition to iDC, Defr1 is a chemoattractant
for CD4
1 T cells from both human and mouse. The analogues
Defr1-Y5C and 1c
V also chemoattract the CD4 T cells but at
reduced activity. Previous studies with the b-defensin HBD3 has
shown that although the disulphide bonds are not essential for
antimicrobial properties, they are essential for the peptide’s
chemoattractant activity [6]. Replacing the cysteine residues with
a-aminobutyric acid yielded an antimicrobially active HBD3
molecule that did not induce the migration of either monocytes
or HEK293 cells expressing CCR6 at concentrations greater than
10000ng/mL. Defr1 contains ﬁve cysteines, Defr1-1c
v contains
only one cysteine residue at the ﬁfth position in the six cysteine
motif and Defr1Y5C contains the canonical six cysteines. Defr1 is
a mixture of dimeric isoforms, whereas Defr1-Y5C is a single
species that conforms to the b-defensin connectivity and is a non-
covalent dimer [15]. Defr1-1c
V is a covalent dimer through the
single cysteine [16]. All three peptides however induce migration
of the human and mouse CD4
1 T cells, but Defr1 has a higher
optimal migration index of 9 compared with 5.5 for Y5C and
Defr1-1c
V and its peak is at a value of 10ng/mL, tenfold more
active than that of Defr1 Y5C and Defr1-1c
V against human cells.
Thus, despite the differences in sequence, Defr1, Defr1 Y5C
and Defr1-1c
v can chemoattract CD4 T cells and Defr1 Y5C with
its canonical connectivity has activity equivalent to the single
cysteine peptide. This is in contrast to iDC, which are only
chemoattracted towards the peptides encoded by Defr1 and Defb8
(Fig. 1).
One possible explanation of these data is that Defr1 can
interact with two receptors on CD4 T cells to induce chemoat-
traction and the analogues Defr1 Y5C and 1c
V can only interact
with one of these receptors. Only one of these receptors – the one
the analogues do not interact with – is on iDC. This would
explain the increased afﬁnity of Defr1 for CD4 T cells compared
with the analogues, and the lack of ability of the analogues to
chemoattract iDC. Alternatively, Defr1 has a higher afﬁnity for a
Figure 4. Defb8, like Defr1, chemoattracts iDC but not mDC and
neither Defb8 nor Defr1 act through CCR6. (A) The ability of Defb8 to
chemoatttract DC cells was assessed by chemotaxis assay. SDF1a
(CXCL12a) was used as a positive control. (B) Defr1, Defb8, Defr1Y5C
and Defr1-1c
V were tested to see if they chemoattracted HEK293 cells
expressing human CCR6. CCL20 was included as a positive control to
indicate these cells do express CCR6. Data shown are the mean
number of cells migrated per high power ﬁeld of view from a total of
nine random ﬁelds from three replicate wells and are from one
experiment from a minimum of three. Error bars represent SD of all
nine replicate counts. p o 0.05, signiﬁcantly higher cell number than
medium alone control.
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single cysteine analogues and iDC have a different receptor that
enables cell migration towards Defr1 but not to the analogues.
We also show here that mouse strains either have a Defb8
encoding gene or a Defr1 encoding gene. We suggest that Defb8 is
allelic with Defr1 and that Defr1 most likely arose in the M. musculus
domesticus contribution to the C57Bl/6 inbred strain. Recently, it has
been shown that the majority of genetic contribution to inbred
mouse strains is from M. musculus subspecies – M. m. domesticus,
M. m. musculus, M. m. castaneus and the hybrid M. m. molossinus
[ 2 2 ] .W es h o wh e r et h a taDefr1 PCR product was only observed in
C57Bl/6 and the M. m. domesticus wild strain Lewes EiJ. The species
that did not give a PCR band presumably were too divergent to allow
primer annealing as this happened in species that were not
M. musculus. Of the other M. musculus sub species, M. m. musculus
(CZECHI) gave a Defb8 fragment as did M. m. castaneus. We have
also ampliﬁed a fragment from M. m. molossinus (MOLF Ei/J) using
the Defb8-speciﬁc primers (data not shown) and the Defr1 primers
ampliﬁed a product from WSB/EiJ,w h i c hi sa n o t h e rM. m. domes-
ticus strain [23]. The 3bp differences between the two coding
sequences give rise to three amino acid changes. Both Defr1 and
Defb8 can chemoattract lymphocytes, but Defb8 has a much reduced
antimicrobial activity compared with Defr1 (data not shown) and
similar to the six cysteine peptide Defr1 Y5C [15]. Thus the M. m.
domesticus-derived Defr1 sequence may have been subject to positive
selection with susceptibility to microbes as the selective pressure.
In order to assess if Defr1, Defr1Y5C, Defr1-1c
V or Defb8 utilise
the chemokine receptor 6 (CCR6), as has been demonstrated for
other b-defensins, we used HEK293 cells expressing CCR6. These
cells express human CCR6 and have been used by us previously to
demonstrate the chemoattractant properties of mouse b-defensin
D e f b 1 4 ,D e f b 2a n dH B D[ 6 ,9 ] .N om i g r a t i o no ft h e s ec e l l si s
observed when they are exposed to these related peptides indicat-
ing that these peptides do not use CCR6 within this chemotaxis
assay. Previous analysis with both human and mouse b-defensins
including the Defb2 (mBD2) fusion has displayed the importance of
CCR6 in migration, with this being highlighted as the receptor
involved [3, 13]. However, other work has suggested this is not the
only receptor with which b-defensins can interact. HBD3 displays
chemoattractant properties for monocytes, which do not express
CCR6, indicating an additional receptor can be recognised by this
defensin [6]. No studies have currently revealed what this receptor
is but Defb8 has also been reported to mobilise macrophages so it is
possible that it uses the same receptor [17]. LL-37 has been shown
to act through the formyl peptide receptor-like 1, as a receptor to
chemoattract human peripheral blood neutrophils, monocytes and
T cells [20], but this seems unlikely to be the receptor implicated
here as we show here that Defr1 does not chemoattract neutrophils.
The molecular detail behind the receptor-mediated chemo-
tactic activity of b-defensins is not clear. Studies of HBD3
isoforms with different disulphide connectivities show alteration
of chemotactic activities against CCR6 expressing cells and
monocytes. Comparison of b-defensins and CCL20 (MIP3a) has
led to suggestions of similarly structured motifs being present in
both molecules despite no obvious sequence similarity [24].
The ability of defensins to chemoattract cells expressing CCR6
has been demonstrated independently by several groups includ-
ing our own [3, 9, 25, 26] However Soruri et al. [17] recently
reported that they found HBD1–4 do not utilise CCR6 and do not
induce migration of DC or CD4 T cells but do induce migration of
macrophages. One of the peptides they assayed was mBD8
(Defb8) and they show that mBD8 can chemoattract macro-
phages and report that mBD8 cannot chemoattract human or
mouse T lymphocytes. We agree that Defr1 and Defb8 do not
chemoattract cells exogenously expressing CCR6, but we do see
Defb2 and Defr1 attracting CD4 T cells and Defr1, Defb8 and
Defb2 attracting iDC but not mDC. One explanation may be that
their peptide preparations and chemoattraction assay are differ-
ent from ours. They observe an optimal chemoattraction of
macrophages with their HBD3 peptide for example at a concen-
tration tenfold higher than that reported previously for mono-
cytes [6]. However, we see chemoatttraction activity against iDC
both with our own in-house synthesised peptide of Defb8 and a
preparation from the same source as Soruri et al. (Phoenix
Pharmaceuticals) (data not shown) [17].
In summary, these results highlight that Defr1 a novel murine
defensin present in C57Bl/6 genome with only ﬁve cysteines can
chemoattract CD4
1 T cells and iDC but not mDC. Defr1 analo-
gues with the canonical six or only one cysteine can also
chemoattract CD4 T cells but not DC. An alternate Defr1 allele
Defb8, present in other mouse inbred strains and which has three
amino acid differences to Defr1, can also chemoattract iDC but
not mDC. Importantly, none of these peptides can induce
migration of HEK293 cells expressing CCR6.
Materials and methods
CD4
1 T-cell isolation from mouse
CD4
1 T cells were isolated by a mini MACS magnetic sorter
(Miltenyi Biotech, UK) using a positive selection protocol
according to the manufacturer’s instructions.
Human monocyte and T-cell isolation
Mononuclear cells were isolated from human peripheral blood or
bone marrow from normal donors by routine Ficoll–Paque
density gradient centrifugation as described previously [6].
Culture of bone marrow-derived DC
Bone marrow cells were isolated from mouse tibia and femur
bones as previously described [27]. Brieﬂy bone marrow-derived
cells were adjusted to give 3.75 10
5cells/mL in complete media
supplemented with 5% (500U/mL) of supernatant from a
GM-CSF-expressing cell. The GM-CSF supplemented culture
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harvested on day 6 or 7. mDC were obtained by incubating day 6
cultures for 24h with the addition of 100ng/mL of Escherichia
coli LPS.
FACS analysis
Identiﬁcation of the cell population was conducted by ﬂuorescent
analysis for expression of cell surface markers using FACScan
ﬂow cytometer (Coulter Corporation, USA). All antibodies
were purchased from Pharmingen/Becton Dickson (USA). The
labelling antibodies used and the corresponding isotype,
used as a speciﬁcity control. Splenic CD4
1 T cells were double
stained for CD4 (FITC anti-mouse CD4 (L3T4)) and CD3
(PE anti-mouse CD3e). DC were analysed by double staining
for CD11c (PE anti-mouse CD11c (HL3)) and MHC II expression
(FITC anti-mouse I-A
b (AB
b), and single stained for CD54 (PE
anti-mouse (ICAM-1) and CD86 (PE anti-mouse CD86 (B7-2)
expression. Contamination was assessed by single staining
for Gr1 (PE anti-mouse Ly-6G) and CD45 (FITC anti-mouse
CD45/B220).
Chemotaxis assay
Chemotaxis was perfomed using 48-well chemotaxis chambers
(Neuro Probe, Gaithersburg USA) as described previously [3, 6]. The
i n c u b a t i o nt i m ew a s1 . 5 hf o rD C ,4 hf o rTc e l l sa n d5 hf o r
transfected HEK293 cells. The cells were suspended in, and all
chemotactic factors were diluted with, chemotactic medium (CM)
RPMI 1640 containing 1% BSA). Cells are resuspended at 5 10
5
per mL and 200mL is added to each upper assay chamber. All murine
chemokines were purchased from PeproTech EC (London, UK)
dissolved in RPMI/1% BSA. Three random ﬁelds of view at  400
magniﬁcation were counted for every well. Samples were performed
in triplicate. The MI was also calculated as the ratio of the number of
migrated cells at the optimal peptide concentration to the number of
cells in the control well was not exposed to peptide. Statistical
analysis was carried out using a one-tailed Student’s t-test.
Defr1/Defb8 PCR
PCRs for Defr1 and Defb8 were carried out using the same 30 reverse
primer (GGTTTGCAGGATCTTTGT) for both but allele-speciﬁc
primers for each. The Defr1-speciﬁc forward primer is
50ATCAATGATCCAGTAACTTAC and the Defb8-speciﬁc primer is
50ATCAATGAACCAGTAAGTTGC. All samples were subjected to a
Defr1 and a Defb8 PCR. The annealing temperature for the PCRs is
541Cf o rD e f r 1a n d5 2 1C for Defb8. Following gel electrophoresis of
the samples after PCR, the gels were subjected to Southern blot
analysis and probed with an internal oligonucleotide of
sequence 50CTTATGAAGGCCAATGC with a 100% bp match to both
sequences.
Peptide synthesis
All b-defensin peptides were chemically synthesised by standard
solid phase methodology. Defb2; Defr1, Defr1Y5C and Defr1-1c
V
(see Table 1 for sequence) were obtained from Chemical
Synthesis Services (Gladsmuir, UK). Defb8 was synthesised ‘‘in
house’’ using automated peptide synthesis see Supporting
Information for additional information on peptide synthesis,
puriﬁcation, oxidation and determination of the disulphide
connectivity).
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